Subsequent work evaluating a wider panel of breast cancer cell lines with different phenotype (e.g., hormone receptor positive, HER-2 amplified, or triple-negative cell lines) demonstrated that TRAIL agonists preferentially induced apoptosis in TNBC (including MDA-MB-231) [30]. This evidence concerns the gene NR4A1 and breast carcinoma.